Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNTB 2.00 -0.02(-0.99%)
Will CNTB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTB
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTB
Connect Biopharma (CNTB) Expands Board with New Director Appointment | CNTB Stock News
Connect Biopharma (CNTB) Gains Attention with Promising Treatment | CNTB Stock News
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors | CNTB ...
Northland Begins Coverage on Connect Biopharma (CNTB) with Positive Outlook | CNTB Stock News
Connect Biopharma announces expansion of board, appoints Schoeneck as director